Equities

SyntheticMR AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

SyntheticMR AB (publ)

Actions
  • Price (SEK)1.12
  • Today's Change0.02 / 1.82%
  • Shares traded8.44k
  • 1 Year change-72.34%
  • Beta0.6050
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

SyntheticMR AB (publ) is a Sweden-based company that develops and markets software solutions for Magnetic Resonance Imaging (MRI). The Company provides SyMRI, which measures the absolute properties of the brain and delivers adjustable contrast images, automatic biomarker segmentation and quantitative data in a single MR scan. The SyMRI product is available in different packages. SyMRI IMAGE provides fast MRI workflows, allowing high patient throughput. SyMRI NEURO enables automatic segmentation of brain tissue, providing objective decision support. SyMRI Research Edition includes exportable SyMaps, parametric common contrast weighted images and maps of the brain, allowing the investigation to be taken even further. SyMRI is a registered trademark in Europe and in the USA.

  • Revenue in SEK (TTM)57.05m
  • Net income in SEK-54.93m
  • Incorporated2007
  • Employees41.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Neola Medical AB0.00-10.99m59.24m8.00--0.755-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Luxbright AB11.49m-19.25m60.00m12.00--2.23--5.22-0.1644-0.16440.09680.20670.27887.732.68---46.74-56.30-59.61-66.28-6.22-79.12-167.60-450.361.22-83.810.1076--26.5279.40-9.86------
Kontigo Care AB29.13m-2.07m62.22m10.00--1.2317.202.14-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Episurf Medical AB16.10m-58.10m64.55m18.00--1.36--4.01-0.0533-0.05330.01380.02860.2043--4.54894,444.40-72.97-47.42-86.27-52.18-----357.14-701.121.41-579.000.0935--22.9018.1323.42--7.81--
Redsense Medical AB (publ)30.67m302.00k70.88m4.00215.181.97119.932.310.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB11.68m-8.70m81.56m1.00--14.17--6.98-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
BibbInstruments AB149.00k-13.30m82.29m4.00--1.93--552.30-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
Bioretec Oy-1.06tn-1.06tn96.64m57.00---------------------------57.56---77.31--70.90---128.20--------16.3221.07-21.78------
SyntheticMR AB (publ)57.05m-54.93m100.05m41.00--0.678--1.75-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Observe Medical ASA15.77m-116.22m105.06m4.00--4.29--6.66-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
Iconovo AB1.59m-41.23m105.79m19.00--0.4465--66.66-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Arcoma AB132.94m4.35m108.74m31.0023.711.489.390.8180.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Immunovia AB (publ)785.00k-125.52m119.60m9.00------152.36-0.3569-0.35690.0024-0.0210.0156--0.26487,222.22-249.16-48.08-827.53-52.27-7,231.59-6,932.30-15,989.68-17,625.510.6282-3.001.68---40.8921.2075.26------
iZafe Group AB5.90m-17.73m138.19m10.00--8.39--23.42-0.0614-0.06140.01940.04520.17573.448.15843,000.00-52.78-57.76-73.42-72.44-106.29-287.24-300.41-630.900.9122-17.450.0198--336.55-11.1036.26---24.50--
Scandinavian Medical Solutions A/S348.42m36.91k138.94m28.005,333.331.1811.180.39880.00070.00078.882.991.291.9411.19--0.01376.590.024611.6823.1224.880.01064.680.35241.140.4345--8.2842.38-99.67-64.34----
Scandinavian Real Heart AB0.00-38.87m139.96m12.00--0.8386-----16.17-16.170.0016.690.00----0.00-44.53-27.49-52.77-30.65-------12,518.77----0.0678------49.47--6.59--
Data as of Feb 16 2026. Currency figures normalised to SyntheticMR AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

5.80%Per cent of shares held by top holders
HolderShares% Held
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 20252.02m2.26%
Swedbank Robur Fonder ABas of 30 Jan 20261.75m1.96%
Aktia Bank Plc (Investment Management)as of 31 Oct 20251.41m1.58%
AIFM Capital ABas of 30 Jun 20243.75k0.00%
More ▼
Data from 28 Nov 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.